Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma
Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.
Neurophos Raises $7.2 Million Round to Create Super-fast, Energy-Efficient Metamaterial-Based Optical AI Chips for Data Centers
Neurophos is a metamaterial-based start-up developing optical computing chips. It was founded by PhD graduate Patrick Bowen and spun out of the lab of Professor David Smith (ECE, Pratt).
Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim
Ten63 is a Duke University start-up and DCP portfolio company out of the lab of Professor Bruce Donald (Computer Science, Trinity).
Tune Therapeutics Presents First Data Supporting TUNE-401: a First-in-Class Epigenetic Silencer for Hepatitis B
Tune Therapeutics is a Duke start-up and DCP portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).
Invented at Duke 2023 showcases a bustling innovation ecosystem
Featuring inventor booths, innovation resources, and strong support in speeches from leaders, Invented at Duke 2023 caps a big year for OTC.
New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
This application of vorasidenib is based on licensed technology developed by Dr. Darell Bigner (Neurobiology, SOM) and colleagues.
Gilhuly Accelerator Fund Invests Over $1M in Duke Inventor Projects in its Inaugural Year
The Duke community, led by Trustee Ned Gilhuly, is supporting Duke inventors with its newest translational fund dedicated to accelerating the development of early-stage technologies with high commercial potential.
NCBiotech Awards $2.75 Million in Grants, Loans in Latest Quarter
Two Duke start-ups received loans & four Duke projects received Translational Research Grants. Recipients hail from across the university!
Synthetic Antibiotic Could Be Effective Against Drug-Resistant Superbugs
Decades of work by a series of Duke investigators yields new drug, patents and a startup company Valanbio Therapeutics